Aggressive XXXX characterized by rapid disability progression.

@entity1 @entity19383 @entity146
BACKGROUND: Criteria for identifying @entity19383 ( @entity19383 ) @entity1 with @entity146 , which would be useful for clinical decision making, are currently unavailable. OBJECTIVE: Identify @entity19383 @entity1 with @entity146 characterized by rapid disability progression. METHODS: Data from a 2-year, phase 3, double-blind, placebo-controlled trial with long-term follow-up evaluations of @entity19383 @entity1 taking either intramuscular interferon beta-1a (IM IFNb-1a, 30 g) or placebo with baseline Expanded Disability Status Scale (EDSS) scores of 1.0-3.5 were retrospectively analyzed. @entity1 with a >= 2.0-point increase in EDSS score, resulting in a score >= 4.0 by study end, were considered to have @entity146 @entity19383 . The risk of a poor long-term outcome, defined as an EDSS score >= 8.0 at 8 years of follow-up, was calculated as an odds ratio from a logistic regression model comparing @entity1 with and without @entity146 @entity19383 . RESULTS: Only 25 @entity1 met the criteria for @entity146 @entity19383 . Among these @entity1 , mean disease duration was 5.1  3.85 years, mean baseline age was 37.2  6.35 years, and mean baseline EDSS score was 2.8  0.74. Fewer IM IFNb-1a-treated than placebo-treated @entity1 met the criteria for @entity146 @entity19383 at 2 years (7% vs 22% on placebo, p=0.0072). Thirteen @entity1 reached the EDSS milestone of >= 8.0 by the end of the 8-year follow-up. The odds ratio for attaining severe disability was 86.4 (95% CI, 10.3-726.4; p<0.0001) for @entity1 with @entity146 @entity19383 compared to @entity1 without @entity146 @entity19383 . CONCLUSIONS: Defining @entity146 @entity19383 based on rapid EDSS progression was useful in identifying @entity1 at risk for more severe disease course.
